FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula I or its pharmaceutically acceptable salt, wherein R1, R5 are independently selected from H; R2, R3 and R4 are selected from H and ring A, wherein one of R2, R3 or R4 independently represents ring A; ring A is a 6-member monocyclic or 10-member bicyclic aromatic ring which optionally contains 1 heteroatom, which is N, wherein ring A can be optionally substituted with 1-3 substitutes independently selected from halogen, OH, COOH, C1-C6-alkyl, C1-C6-alkoxy, -C(O)C1-C6-alkyl, -NO2; ring B is a 5-6-member non-aromatic ring, optionally containing 1 heteroatom, which is O, wherein ring B can be optionally substituted with 1-3 substitutes independently selected from -C1-C6-alkyl, -C(O)C1-C6-alkyl, -C1-C6-alkoxy; R6 is selected from H or C1-C6-alkyl, R7 denotes H or-(Z)m-(D)p, where independently m=0-1, p=0-1, wherein m=p=0 does not hold; Z is selected from C1-C6-alkyl; D is a 5-6-member non-aromatic ring, optionally containing one N heteroatom, wherein ring D can be optionally substituted with one substitute selected from C1-C6-alkyl, C1-C6-alkoxy. Compound of formula I or pharmaceutically acceptable salt thereof are intended for use as sst4 receptor agonist for preparing a pharmaceutical composition for treating and/or preventing a pathological condition or disease involving somatostatin receptors subtype 4 (sst4). Invention also relates to a pharmaceutical composition for treating and/or preventing a pathological condition or disease, treatment and/or prevention of which requires use of somatostatin receptor agonist subtype 4 (sst4), containing a therapeutically effective amount of compound of formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, solvent and/or filler.
EFFECT: chemical compounds, which are selective agonists of human sst4 receptors.
15 cl, 4 dwg, 3 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRIDINES, DEMONSTRATING PROPERTIES OF ANTAGONISTS OF ADENOSINE A2A RECEPTORS, AND THEIR APPLICATION | 2013 |
|
RU2534804C1 |
| PHENOXY-SUBSTITUTED PYRIMIDINES FOR APPLICATION AS OPIOID RECEPTOR MODULATORS | 2010 |
|
RU2554870C2 |
| 2-PYRAZINONE DERIVATIVES FOR TREATING DISEASES OR CONDITIONS WHERE INHIBITING NEUTROPHIL ELASTASE ACTIVITY IS USEFUL | 2007 |
|
RU2448098C2 |
| DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS CONTAINING THEM, OBTAINING AND APPLICATION | 2004 |
|
RU2346938C2 |
| OXYINDOLE DERIVATIVES POSSESSING AGONIST ACTIVITY ON MOTILIN RECEPTOR | 2010 |
|
RU2533116C2 |
| SUBSTITUTED BENZOAZEPINES AS MODULATORS OF TOLL-LIKE RECEPTORS | 2010 |
|
RU2593261C2 |
| COMPOUNDS AND COMPOSITIONS AS MODULATORS OF HEDGEHOG PATHWAY | 2007 |
|
RU2413718C2 |
| 1-IMIDAZOLE DERIVATIVES AS MODULATORS OF CANNABINOID RECEPTORS | 2004 |
|
RU2337907C2 |
| CYTOTOXIC AND ANTIMITOTIC COMPOUNDS AND METHODS OF USING THEM | 2015 |
|
RU2723651C2 |
| BETA-CARBOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF AND METHODS FOR BINDING, ATTAINMENT OF AGONISTIC/ANTAGONISTIC EFFECT | 1999 |
|
RU2233841C2 |
